ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jul 28, 2020 12:00 JST
Source:
Theragen Bio Co Ltd
Theragen Bio analyzes Korea's largest COVID-19 patient and coronavirus genomic data
SEOUL, S.KOREA, Jul 28, 2020 - (ACN Newswire) - Theragen Bio is conducting joint research on developing a new coronavirus (COVID-19) genomic big data in collaboration with the Korea Research Institute of Chemical Technology (KRICT), Kyungpook National University Hospital, and the Daegu Metropolitan Government.
The study will analyze the full genome of each patient and the SARS-CoV-2 virus using samples from approximately 1,000 COVID-19 patients in Daegu and Gyeongsangbuk-do provence, the largest coronavirus genomic analysis to be conducted in Korea.
Through this study, Theragen hopes to identify the infection correlation between patient genome and the SARS-CoV-2 virus genome, and apply it to future vaccine development. Theragen identified the genetic correlation while establishing big data for SARS-CoV-2 mutations.
Based on its own Next Generation Sequencing (NGS), Theragen's ultra-sensitive Covid-19 RNA analysis system can decode over 30,000 full-legnth RNA sequences per virus. The SARS-CoV-2 virus mutates frequently, however the system can check RNA mutation, replication, and generation.
In addition, the evolution of the SARS-CoV-2 virus can be traced back to understand the transmission mechanisms between humans and predict clinical patterns, identify high-risk groups, improve the efficiency of PCR-based diagnosis, and secure evidence for prevention and prevention strategies.
Hwang Tae-soon, the CEO of Theragen Bio, explains, "This research is the first attempt to analyze whether there are differences in infection susceptibility depending on the genetic predisposition of infected patients as well as mutations and the evolution of the virus. It will be applicable to various infectious diseases in the future, as well as clinical prediction and vaccine development."
In April, Theragen Bio collaborated on research for a high-resolution genetic map of SARS-CoV-2, developed by Narry Kim, head of the RNA research group at the Institute for Basic Science (IBS), Hyeshik Chang, a professor at the Department of Biological Sciences, Seoul National University, in collaboration with Korea National Institute of Health (KNIH) within Korea Centers for Disease Control & Prevention (KCDC).
This study found the location of the coronavirus gene and RNA variations, to identify the transcriptome composition and the proliferation principles of the virus. In May, Theragen Bio traced the Seoul Itaewon cluster infections by sequencing the genomic materials and RNA transcriptomes and found that this SARS-CoV-2 variation originated in the U.S.
Theragen Bio, formerly the genome division of Theragen Etex (Kosdaq:066700), was spun off in March, 2020 to actively pursue customized pharmaceutical & new drug development and other projects featuring genomic technology. For further iniformation, please visit www.theragenbio.com.
Contact: Hyun Kim
Theragen Bio Co., Ltd.
Tel: +82-31-888-9313
Email:
ngssales@theragenetex.com
Website: www.theragenbio.com
Source: Theragen Bio Co Ltd
Sectors: Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
DENSO Acquires Axia Vegetable Seeds to Realize Sustainable Agriculture
Jul 04, 2025 16:20 JST
MHIET Launches 450kW Gas Cogeneration System Capable of Hydrogen Co-Firing
Jul 04, 2025 15:13 JST
Yachiyo Engineering and NEC launch adaptation finance study in Indonesia to calculate the adaptation value of disaster prevention measures
Jul 04, 2025 13:25 JST
Fujitsu to implement store monitoring solution for METRO Inc. in Canada, enhancing operational efficiency and policy compliance
Jul 04, 2025 13:19 JST
Fujitsu to develop ETF trading platform based on TSE's CONNEQTOR and provide it to Australian Securities Exchange
Jul 03, 2025 11:14 JST
Mitsubishi Motors Launches the All-New Grandis for the European Market
Jul 02, 2025 12:10 JST
Valuufy partners with Mainichi Future Creation Lab, Supporting New Approaches to Business Sustainability
Jul 02, 2025 12:00 JST
Fujitsu launches solution to enhance customers' global supply chain resilience
Jul 02, 2025 11:32 JST
MHI Receives Order to Supply Four Circulating Water Pumps for Units 5 and 6 of Sanmen Nuclear Power Plant in China Under Collaboration with Dongfang Electric Machinery
Jul 02, 2025 11:30 JST
Multi-purpose Arena in Odaiba Aomi Area TOYOTA ARENA TOKYO Construction Completed
Jul 01, 2025 22:56 JST
1Finity, a Fujitsu company, commences operations and reveals brand identity
Jul 01, 2025 22:53 JST
MHI Thermal Systems Begins Field Test of Jointly Developed "Surplus Renewable Energy Absorption and Release System"
Jul 01, 2025 22:40 JST
Japan's Telecommunications Carriers Strengthen Disaster Response Through Collaborative Information Sharing
Jul 01, 2025 22:30 JST
JCB and Mandai Wildlife Group Deepen Partnership with exclusive discounts for JCB cardmembers
Jul 01, 2025 16:00 JST
Fujitsu provides Japan's first AI-powered cloud-based library search service
Jul 01, 2025 11:30 JST
JCB Brings Apple Pay to Cardmembers in Vietnam
Jul 01, 2025 11:15 JST
First Shipment of LNG from the LNG Canada Project
Jul 01, 2025 11:00 JST
Approval in Principle (AiP) for World's First LCO2 / Methanol Carrier
Jun 30, 2025 20:30 JST
Acropolis Rally Greece: Day 4 Sunday success and second overall for TOYOTA GAZOO Racing's Ogier
Jun 30, 2025 20:15 JST
Mitsubishi Fuso-Hino Merger: 4 Firms Collaborate for the Future of Commercial Vehicles
Jun 30, 2025 20:10 JST
More Latest Release >>